In methicillin-susceptible S aureus bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin for 90-d mortality.

Cefazolin is noninferior to flucloxacillin or cloxacillin for 90-day mortality in methicillin-susceptible Staphylococcus aureus bacteremia.

• Why it matters: This finding addresses the need for effective and potentially more accessible antibiotic options for treating MSSA bacteremia, which can have high mortality rates.
• What they did: The study compared cefazolin with flucloxacillin or cloxacillin in a clinical setting, assessing 90-day mortality outcomes in patients with MSSA bacteremia.
• The result: Results showed cefazolin's efficacy was comparable, enabling clinicians to consider cefazolin as a viable alternative, potentially improving treatment flexibility and patient outcomes.